Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 1/2010

01-07-2010 | Gynecologic Oncology

GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients

Authors: Markus Nitzschke, Juliane Raddatz, Michael K. Bohlmann, Petra Stute, Thomas Strowitzki, Michael von Wolff

Published in: Archives of Gynecology and Obstetrics | Issue 1/2010

Login to get access

Abstract

Purpose

To determine the protective effect of gonadotropin-releasing hormone analogs (GnRHa) using several ultrasound and endocrine markers to detect ultrastructural ovarian damage in Hodgkin’s lymphoma patients.

Methods

Ten patients who had been treated for Hodgkin’s lymphoma and had received GnRHa to protect ovarian function were matched with patients at similar age, who had received the same chemotherapy regimens without GnRHa. In addition, ten healthy women at the same age were matched to the study groups to compare ovarian markers. Blood samples were drawn to determine anti-Müllerian hormone, Inhibin B, follicle-stimulating hormone and transvaginal ultrasound scans were performed to determine antral follicle count and ovarian volume. All women were asked about their menstrual cycle pattern.

Results

No difference was found when comparing the ovarian parameters of both study groups. Compared with healthy women, all ovarian parameters in the Hodgkin’s lymphoma patients were significantly different.

Conclusions

The results of this study demonstrate ultrastructural ovarian damage in Hodgkin’s lymphoma patients irrespective of GnRHa co-treatment. These findings do not support previous studies, showing GnRHa to protect ovarian function.
Literature
1.
Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7:535–543CrossRefPubMed
2.
Sonmezer M, Oktay K (2004) Fertility preservation in female patients. Hum Reprod Update 10:251–266CrossRefPubMed
3.
Blumenfeld Z, Avivi I, Ritter M, Rowe JM (1999) Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 6:229–239CrossRefPubMed
4.
Glode LM, Robinson J, Gould SF (1981) Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1:1132–1134CrossRefPubMed
5.
Oktay K, Sönmezer M, Oktem O, Fox K, Emons G, Bang H (2007) Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 12:1055–1066CrossRefPubMed
6.
Blumenfeld Z, von Wolff M (2008) GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 14:543–552CrossRefPubMed
7.
Beck-Fruchter R, Weiss A, Shalev E (2008) GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14:541–542CrossRef
8.
Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, Bastian LA (2009) Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 18:311–319CrossRef
9.
Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697CrossRefPubMed
10.
Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA (2003) Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18:2368–2374CrossRefPubMed
11.
Larsen EC, Müller J, Rechnitzer C, Schmiegelow K, Andersen AN (2003) Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH < 10 IU/l. Hum Reprod 18:417–422CrossRefPubMed
12.
Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21:2583–2592CrossRefPubMed
13.
Avril C (2006) Antral follicle count and oocyte quality. J Gynecol Obstet Biol Reprod 35:2S42–2S43
14.
Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ et al (2000) Ovarian volume related to age. Gynecol Oncol 77:410–412CrossRefPubMed
15.
Ataya K, Pydyn E, Ramahi-Ataya A, Orton CG (1995) Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: preliminary observations. J Clin Endocrinol Metab 80:790–795CrossRefPubMed
16.
Ataya K, Rao LV, Lawrence E, Kimmel R (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52:365–372CrossRefPubMed
17.
Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S et al (1987) Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 19:159–162CrossRefPubMed
18.
Sverrisdottir A, Nystedt M, Johansson H, Fornander T (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567CrossRefPubMed
19.
Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF (1998) Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 22:989–994CrossRefPubMed
20.
Grigg AP, McLachlan R, Zaja J, Szer J (2000) Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 26:1089–1095CrossRefPubMed
21.
Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G (1985) Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601–605CrossRefPubMed
22.
Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12:141–147CrossRefPubMed
Metadata
Title
GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients
Authors
Markus Nitzschke
Juliane Raddatz
Michael K. Bohlmann
Petra Stute
Thomas Strowitzki
Michael von Wolff
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 1/2010
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-009-1308-5

Other articles of this Issue 1/2010

Archives of Gynecology and Obstetrics 1/2010 Go to the issue

Materno-Fetal Medicine

Does amnioinfusion reduce caesarean section rate in meconium-stained amniotic fluid

Materno-fetal Medicine

Critical appraisal of case–control studies of risk factors or etiology of Hyperemesis gravidarum

General Gynecology

Detrusor overactivity: an overview

General Gynecology

Long-term effects of extracorporeal magnetic innervations in the treatment of women with urinary incontinence: results of 3-year follow-up

Letter to the Editor

Primary peritoneal carcinoma: a diagnostic dilemma

Letter to the Editor

Non-traumatic rupture of the left upper urinary tract during pregnancy without discernable underlying disorders